{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T21:05:16Z","timestamp":1774040716198,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T00:00:00Z","timestamp":1655251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["100523073"],"award-info":[{"award-number":["100523073"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014913","name":"Freistaat Sachsen","doi-asserted-by":"publisher","award":["100523073"],"award-info":[{"award-number":["100523073"]}],"id":[{"id":"10.13039\/501100014913","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST 268\/387-1"],"award-info":[{"award-number":["INST 268\/387-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The rapid development, approval, and production of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in less than 1 year after the first reports of a new infectious disease was a real game changer, providing 80%\u201390% efficacy in preventing severe etiopathologies of the coronavirus disease 2019 (COVID-19). These vaccines induce an immune response against the SARS-CoV-2 spike (S) protein located on the surface of the virus particle. Antibodies (Abs) recognizing the S-protein can inhibit binding of the virus <jats:italic>via<\/jats:italic> the S-protein to the angiotensin-converting enzyme-2 (ACE-2) receptor expressed on different human cells, especially when these Abs bind to the interaction site, the so-called receptor-binding domain (RBD). We have expressed the RBDs of wild-type SARS-CoV-2 and five variants of concern (VOCs) to test the immune response in people before vaccination with mRNA vaccines BNT162b2 and mRNA-1273 and after up to three vaccinations using in-house ELISA and inhibition assays. The methods of both assays are provided. Both vaccines initiated similarly high IgG titers after two vaccinations against the wild-type and even two VOC-RBDs (alpha and delta) and strongly inhibited the corresponding RBD-ACE-2 binding. The IgG titers and inhibition of ACE-2 binding were lower for beta and gamma RBDs and much lower for omicron RBD. The third vaccination after 6 months strongly increased both the IgG titers and the neutralizing effect against all variants, especially for omicron, leading to 63% \u00b1 13% neutralization potential. Importantly, neutralization linearly increased with the IgG titers.<\/jats:p>","DOI":"10.3389\/fimmu.2022.915034","type":"journal-article","created":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T05:18:02Z","timestamp":1655270282000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Cross-Reactivity of IgG Antibodies and Virus Neutralization in mRNA-Vaccinated People Against Wild-Type SARS-CoV-2 and the Five Most Common SARS-CoV-2 Variants of Concern"],"prefix":"10.3389","volume":"13","author":[{"given":"Mandy","family":"Schwarze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andor","family":"Krizsan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Brakel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Pohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Volke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04188-6","article-title":"The Emergence, Genomic Diversity and Global Spread of SARS-CoV-2","volume":"600","author":"Li","year":"2021","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 Vaccines in Development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2021.02.007","article-title":"Insights Into SARS-CoV-2 Evolution, Potential Antivirals, and Vaccines","volume":"558","author":"Abdel-Moneim","year":"2021","journal-title":"Virology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and Its Immune Cross-Reactivity With SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/v13010134","article-title":"Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies","volume":"13","author":"Finkelstein","year":"2021","journal-title":"Viruses"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-00523-5","article-title":"Linear Epitopes of SARS-CoV-2 Spike Protein Elicit Neutralizing Antibodies in COVID-19 Patients","volume":"17","author":"Li","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n445","article-title":"Covid-19 and Evolutionary Pressure: Can We Predict Which Genetic Dangers Lurk Beyond the Horizon","volume":"372","author":"Green","year":"2021","journal-title":"BMJ"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e61312","DOI":"10.7554\/eLife.61312","article-title":"Escape From Neutralizing Antibodies by SARS-CoV-2 Spike Protein Variants","volume":"9","author":"Weisblum","year":"2020","journal-title":"Elife"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0831","article-title":"Antibody Cocktail to SARS-CoV-2 Spike Protein Prevents Rapid Mutational Escape Seen With Individual Antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.1c01451","article-title":"Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance","volume":"62","author":"Chen","year":"2022","journal-title":"J Chem Inf Model"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.781429","article-title":"SARS-COV-2 Variants: Differences and Potential of Immune Evasion","volume":"11","author":"Hirabara","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2022.01.059","article-title":"The Omicron (B.1.1.529) Variant of SARS-CoV-2 Binds to the Hace2 Receptor More Strongly and Escapes the Antibody Response: Insights From Structural and Simulation Data","volume":"200","author":"Khan","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2022.2031311","article-title":"Drastic Decline in Sera Neutralization Against SARS-CoV-2 Omicron Variant in Wuhan COVID-19 Convalescents","volume":"11","author":"Ma","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"B14","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1186\/s12889-015-1983-z","article-title":"The LIFE-Adult-Study: Objectives and Design of a Population-Based Cohort Study With 10,000 Deeply Phenotyped Adults in Germany","volume":"15","author":"Loeffler","year":"2015","journal-title":"BMC Public Health"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1107\/S0907444906029799","article-title":"A Time- and Cost-Efficient System for High-Level Protein Production in Mammalian Cells","volume":"62","author":"Aricescu","year":"2006","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"B16","unstructured":"InvitrogenUSER GUIDE - SARS-CoV-2 Neutralizing Antibody ELISA Kit2021"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 Surrogate Virus Neutralization Test Based on Antibody-Mediated Blockage of ACE2-Spike Protein-Protein Interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"eabi8452","DOI":"10.1126\/scitranslmed.abi8452","article-title":"A High-Throughput Cell- and Virus-Free Assay Shows Reduced Neutralization of SARS-CoV-2 Variants by COVID-19 Convalescent Plasma","volume":"13","author":"Fenwick","year":"2021","journal-title":"Sci Transl Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e00512-20","DOI":"10.1128\/JCM.00512-20","article-title":"Laboratory Diagnosis of COVID-19: Current Issues and Challenges","volume":"58","author":"Tang","year":"2020","journal-title":"J Clin Microbiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn7760","article-title":"SARS-CoV-2 Omicron Variant: Antibody Evasion and Cryo-EM Structure of Spike Protein-ACE2 Complex","volume":"375","author":"Mannar","year":"2022","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3001237","article-title":"Cryo-Electron Microscopy Structures of the N501Y SARS-CoV-2 Spike Protein in Complex With ACE2 and 2 Potent Neutralizing Antibodies","volume":"19","author":"Zhu","year":"2021","journal-title":"PLos Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1038\/s41467-021-23473-6","article-title":"Immune Response to SARS-CoV-2 Variants of Concern in Vaccinated Individuals","volume":"12","author":"Becker","year":"2021","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03681-2","article-title":"Immunogenicity of Ad26.COV2.S Vaccine Against SARS-CoV-2 Variants in Humans","volume":"596","author":"Alter","year":"2021","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2231","article-title":"Neutralising Antibody Escape of SARS-CoV-2 Spike Protein: Risk Assessment for Antibody-Based Covid-19 Therapeutics and Vaccines","volume":"31","author":"Focosi","year":"2021","journal-title":"Rev Med Virol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103544","article-title":"The Impact of Spike N501Y Mutation on Neutralizing Activity and RBD Binding of SARS-CoV-2 Convalescent Serum","volume":"71","author":"Lu","year":"2021","journal-title":"EBioMedicine"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01294-w","article-title":"Resistance of SARS-CoV-2 Variants to Neutralization by Monoclonal and Serum-Derived Polyclonal Antibodies","volume":"27","author":"Chen","year":"2021","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03412-7","article-title":"Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA Vaccine-Elicited Antibodies","volume":"593","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1101\/2021.11.19.21266555","article-title":"Antibody Titers Before and After Booster Doses of SARS-CoV-2 mRNA Vaccines in Healthy Adults","author":"Demonbreun","year":"2021","journal-title":"medRxiv"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0249499","article-title":"Human IgG and IgA Responses to COVID-19 mRNA Vaccines","volume":"16","author":"Wisnewski","year":"2021","journal-title":"PLos One"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.19885","article-title":"Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged \u226560 Years","volume":"326","author":"Eliakim-Raz","year":"2021","journal-title":"JAMA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine Over 6 Months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA Vaccine-Elicited Human Sera","volume":"375","author":"Muik","year":"2022","journal-title":"Science"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","article-title":"Antibody Evasion by the P.1 Strain of SARS-CoV-2","volume":"184","author":"Dejnirattisai","year":"2021","journal-title":"Cell"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1101\/2021.12.28.21268491","article-title":"Neutralization of Ancestral SARS-CoV-2 and Variants Alpha, Beta, Gamma, Delta, Zeta and Omicron by mRNA Vaccination and Infection-Derived Immunity Through Homologous and Heterologous Variants","author":"Bekliz","year":"2021","journal-title":"medRxiv"},{"key":"B35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12985-021-01554-8","article-title":"Impact of the N501Y Substitution of SARS-CoV-2 Spike on Neutralizing Monoclonal Antibodies Targeting Diverse Epitopes","volume":"18","author":"Cheng","year":"2021","journal-title":"Virol J"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.23812\/21-3-E","article-title":"The British Variant of the New Coronavirus-19 (Sars-Cov-2) Should Not Create a Vaccine Problem","volume":"35","author":"Conti","year":"2021","journal-title":"J Biol Regul Homeost Agents"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg6105","article-title":"Neutralization of SARS-CoV-2 Lineage B.1.1.7 Pseudovirus by BNT162b2 Vaccine-Elicited Human Sera","volume":"371","author":"Muik","year":"2021","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03944-y","article-title":"SARS-CoV-2 B.1.617.2 Delta Variant Replication and Immune Evasion","volume":"599","author":"Mlcochova","year":"2021","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1016\/j.cell.2021.03.029","article-title":"Neutralizing and Protective Human Monoclonal Antibodies Recognizing the N-Terminal Domain of the SARS-CoV-2 Spike Protein","volume":"184","author":"Suryadevara","year":"2021","journal-title":"Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.691715","article-title":"Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern","volume":"12","author":"Deshpande","year":"2021","journal-title":"Front Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing Antibodies Against the SARS-CoV-2 Delta and Omicron Variants Following Heterologous CoronaVac Plus BNT162b2 Booster Vaccination","volume":"28","author":"P\u00e9rez-Then","year":"2022","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjab050","article-title":"Rapid Detection of Neutralizing Antibodies to SARS-CoV-2 Variants in Post-Vaccination Sera","volume":"13","author":"Miyakawa","year":"2022","journal-title":"J Mol Cell Biol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.915034\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T05:18:07Z","timestamp":1655270287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.915034\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,15]]},"references-count":42,"alternative-id":["10.3389\/fimmu.2022.915034"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.915034","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,15]]},"article-number":"915034"}}